October 25, 2024 at 12:21 pm

Iterum Therapeutics (ITRM) Jumps 87% on FDA Approval for UTI Treatment ORLYNVAH™

Iterum Therapeutics (Nasdaq: ITRM) has received FDA approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for treating uncomplicated urinary tract infections (uUTIs) in adult women with limited oral treatment options. ORLYNVAH™ becomes the first oral penem antibiotic approved in the U.S. and only the second FDA-approved therapy for uUTIs in over 20 years. This approval, based… [Read More]
October 25, 2024 at 11:01 am

Sketcher’s Becomes Street Fashionable as Q3 EPS Shapes Up By 36% From Last Year

The shoemaker of the “Shape Up” and other comfort-centric footwear Sketchers (SKX), has announced its Q3 financial report and cited EPS of $1.26 vs FactSet $1.16, a 36% increase from last year. Skechers reported record Q3 financial results, with sales of $2.35Bn, an increase of 16% or $323M. The company saw significant growth in both… [Read More]
October 25, 2024 at 10:19 am

PRISM EV: GreenPower is Cashing In On Its Carbon Credits

GreenPower Motor Company Inc. (GP), a leading manufacturer and distributor of all-electric, medium and heavy-duty vehicles, announced today that it has initiated the sale of its tradable emissions compliance credits. These credits were earned under various zero-emission vehicle (ZEV), greenhouse gas (GHG) emissions, fuel consumption, renewable energy, and clean fuel regulations. “Through the manufacturing and… [Read More]
October 25, 2024 at 9:46 am

ANI Pharmaceuticals Launches FDA-Approved Estradiol Gel, 0.06%

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced the FDA approval and commercial launch of its Estradiol Gel, 0.06%, a generic equivalent of EstroGel® Gel, 0.06%. This marks ANI’s latest release in a market with limited competition, providing patients and healthcare providers with increased access to this estrogen therapy. The U.S. market for Estradiol Gel, 0.06% generates… [Read More]
October 24, 2024 at 11:38 am

LifeMD Launches TestoRx, a New Direct-to-Consumer Testosterone Replacement Therapy

Just ahead of Movember, the annual movement to raise awareness of men’s health issues, LifeMD, Inc. (Nasdaq: LFMD) has introduced TestoRx, a new testosterone replacement therapy (TRT) offering through its Rex MD men’s health platform. This telehealth service broadens Rex MD’s offerings by addressing male hypogonadism, a condition where the body produces low levels of… [Read More]
October 24, 2024 at 9:36 am

Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline and Extending Cash Runway into 2026

Transformational Merger Renames Combined Entity to Opus Genetics, Strengthening Position in Inherited Retinal Disease and Ophthalmic Therapeutics with Multiple Near-Term Catalysts Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company, has officially acquired Opus Genetics, Inc., a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). The all-stock transaction unites the complementary strengths… [Read More]